Anta Sports Expands Global Footprint With Strategic Puma Stake 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2016 -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that preliminary clinical data from its lead CDK4/6 inhibitor G1T28 for patients with small-cell lung cancer (SCLC) will be presented at the International Association for the Study of Lung Cancer’s 17th World Conference on Lung Cancer (WCLC), to be held December 4 – 7 at the Messe Wien Exhibition & Congress Center in Vienna, Austria. Details on the poster are as follows:
Title: G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results
Poster Session: PS01
Poster Number: P1.07-002
Date / Time: Monday, December 5, 2:30 p.m. – 3:45 p.m. CET
Location: Hall B of the Messe Wien Exhibition & Congress Center
Presenter: Lowell L. Hart, M.D., Florida Cancer Specialists, Fort Myers, FL
G1 will also present preclinical data on G1T28 in a poster session at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, to be held November 29 – December 2 at the Internationales Congress Center Munich in Munich, Germany. Details on the poster are as follows:
Title: G1T28, a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy
Poster Session: Molecular targeted agents II
Poster Number: P118
Date / Time: Thursday, December 1, 10:15 a.m. – 5 p.m. CET
Location: The Exhibition Hall of Internationales Congress Center Munich
Presenter: Patrick J. Roberts, Ph.D., Pharm.D., Director of Translational Medicine, G1 Therapeutics
About G1T28
G1T28 is a potential first-in-class, short-acting IV CDK4/6 inhibitor being developed to preserve hematopoietic stem cells and enhance immune system function during chemotherapy. G1T28 is being studied in two Phase 1b/2a proof-of-concept trials in patients with small-cell lung cancer: a study in newly diagnosed, treatment-naive patients (NCT02499770), and a study in previously treated patients (NCT02514447).
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in people with cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.
Visit www.g1therapeutics.com for more information.
Contact: Mark Velleca, MD, PhD G1 Therapeutics 919-213-9838 [email protected] Media: Laura Bagby 6 Degrees Communications 312-448-8098 [email protected]
